Androgen
- Generic Name
- Androgen
FDA Approves Neurocrine's Crenessity (crinecerfont) for Congenital Adrenal Hyperplasia
• The FDA has approved Crenessity (crinecerfont) as an adjunctive treatment for congenital adrenal hyperplasia (CAH) in adults and children, marking a significant advancement.
• Crenessity is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production.
• Clinical trials demonstrated that Crenessity enables lower glucocorticoid doses while maintaining or improving androgen control in CAH patients.
• Neurocrine Biosciences expects Crenessity to be commercially available soon, offering a new treatment option for individuals with classic CAH.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath